OpenDDE is introduced, an open-source, all-atom biomolecular foundation model that uses co-folding as the entry point to a scalable AI-driven drug discovery engine and identifies two scaling-law directions for co-folding models.
Abstract
Accurately modeling biomolecular interactions is a central bottleneck in biology and therapeutic discovery. Here, we introduce Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model that uses co-folding as the entry point to a scalable AI-driven drug discovery engine. Rather than treating structure prediction as an isolated endpoint, OpenDDE is designed as a shared structural reasoning layer for modeling sequence-structure-function relationships across biomolecular complexes, enabling complex structure prediction today while providing a foundation for de novo design, affinity estimation, structure-conditioned optimization, and more. OpenDDE integrates advances in all-atom architecture, atomic latent reasoning, inference optimization, and large-scale data processing to achieve IsoDDE-level co-folding accuracy within a reproducible and openly accessible framework. We also identify two scaling-law directions for co-folding models, revealing practical routes for continued improvement through data, model, inference, and training scaling. By releasing training code, inference pipelines, checkpoints, and benchmarks, OpenDDE aims to democratize access to frontier biomolecular intelligence, accelerate global collaboration, and lay an open foundation for next-generation drug discovery systems that can move from predicting molecular structures toward designing, scoring, and optimizing therapeutic candidates for human health.
Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution. However, most existing approaches frame molecular generation as an isolated optimization or a one-to-one matching task, overlooking the shared b...
Dong Xu, Zhang-Fan Yang, Junchuang Cai et al.· IEEE transactions on computa...· 1 citation
Boltz is benchmarked using a curated set of ligand-bound human G protein-coupled receptors from families unseen during training, showing that while Boltz generally predicts receptor backbones accurately, ligand poses can contain significant errors that lead to a limited ability to reproduce experimental affinity data w...
Lichirui Zhang, R. Friesner, Edward B. Miller et al.· npj Drug Discovery· 0 citations
Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.
Pascal Sturmfels, Naozumi Hiranuma, Milad Salem et al.· arXiv.org· 0 citations
TTS-Design is proposed, a test-time compute scaling framework that enhances protein sequence design without retraining models or relying on larger training datasets, and can consistently improve sequence recovery and structural reliability across different backbone models, without retraining or increasing model size.
Zizhe Jin, Yi Zheng, Huan Yee Koh et al.· Proceedings of the Thirty-Fi...· 0 citations
This chapter describes a structure-based computational approach to perform high-throughput ligand screens of chemical libraries using open-source software programs and illustrates this workflow with the enzymatic molecular target NAD(P)H:quinone oxidoreductase1 (NQO1), which is overexpressed in a number of human solid...
Audrey G. Fikes, Melissa C. Srougi· Methods in molecular biology· 0 citations